Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Tenet Healthcare Corporation — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Tenet Healthcare Corporation trades at $271.76 (market cap $21.49B). The key difference: Tenet Healthcare Corporation is far larger — about 2.9× Spyre Therapeutics Inc. Common Stock's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Tenet Healthcare Corporation for 16 Days on average.
| SYRE | THC | |
|---|---|---|
Market Cap | $7.52B | $21.49B |
Volume | 1,441,031 | 599,998 |
Sector | Health | Health |
52-Week High | $108.92 | $280.77 |
52-Week Low | $22.18 | $161.37 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $6.52B | $32.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Tenet Healthcare (THC) trades at $266.91, down 0.69% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with three consecutive quarterly earnings beats and impressive profitability metrics including 82.83% gross margins and 53.31% ROE. Recent news highlights continued investor interest and upcoming Q3 2026 earnings release on October 29.
THC presents a compelling investment case with attractive valuation (P/E 10.32), strong analyst support (81% buy rating), and 6.2% upside to consensus target of $283.36. Key risks include cash flow sustainability for capital return strategy and potential surgical volume pressures. The stock's combination of value pricing and growth execution supports continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
